Bimekizumab – an IL-17A and IL-17F inhibitor – outdid both placebo and IL-12/IL-23 blocker Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic ...

Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...

The FDA has approved Celltrion’s Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for subcutaneous or intravenous use in ... 3 "Plaque psoriasis and psoriatic arthritis are both ...